Comparison of Initial Clinical Presentations between Primary Hyperparathyroidism Patients from New Brunswick and Changsha

Table 2

Comparison between male and pre- and postmenopausal female PHPT patients from New Brunswick and Changsha.

Clinical features	Male (); NB	Male (); CS	Pre-F (); NB	Pre-F (); CS	Post-F (); NB	Post-F (); CS
Age (years)	59.1 ± 10.7^a,b,e	49.3 ± 16.6^c,d	39.4 ± 8.7^b	38.7 ± 9.7^d	63.3 ± 8.6	63.2 ± 7.6
Duration (years)	4.6 ± 6.3	6.7 ± 8.1	3.1 ± 3.2	4.3 ± 6.0	4.7 ± 7.0	6.0 ± 8.2
BMI (kg/m^2)	30.4 ± 4.9^a,e	21.7 ± 3.2	27.4 ± 6.7^c	19.8 ± 4.8^d	29.3 ± 7.0^d	22.3 ± 3.8
Serum Ca (mg/dL)	11.2 ± 0.6^e	13.4 ± 2.2	11.2 ± 0.6^c	13.4 ± 2.7	11.0 ± 0.5^d	12.8 ± 2.2
Serum PTH (pg/mL)	157.7 ± 125.0^b,e	788.4 ± 519.5^d	170.3 ± 156.5^b.c	801.9 ± 637.6^d	122.8 ± 58.5^d	503.2 ± 516.7
25 (OH) D (ng/mL)	27.7 ± 9.3^e	14.3 ± 8.7	26.7 ± 12.7^c	13.9 ± 7.3	30.8 ± 10.9^d	14.2 ± 8.3
Albumin (g/dL)	4.4 ± 0.6^e	3.8 ± 0.5	4.4 ± 0.3^c	4.0 ± 0.5	4.3 ± 0.4^d	3.8 ± 0.7
AKP (U/L)	88.9 ± 33.2^e	384.1 ± 564.8^d	92.3 ± 42.2^c	794.0 ± 1034.3^d	83.2 ± 25.1^d	166.1 ± 234.2
Glucose (mg/dL)	102.8 ± 20.8^e	94.9 ± 27.1	98.3 ± 21.6	87.5 ± 19.7	98.8 ± 18.5	94.1 ± 21.5
Creatinine (mg/dL)	1.09 ± 0.3^a,b	1.3 ± 0.8^c,d	0.6 ± 0.1^b,c	0.9 ± 0.6	0.8 ± 0.2	0.9 ± 0.4
Kidney stone (%)	44% (17/39)^a,b,e	77% (34/44)^c,d	29% (8/28)^c	52% (17/33)	26% (27/102)^d	55.6% (30/54)
Total hip BMD (-score)	−0.697 ± 0.927^a,b,e	−2.532 ± 1.190	−0.167 ± 0.823^b,c	−2.594 ± 1.557	−1.075 ± 1.100^d	−2.439 ± 1.060
L1–4 BMD (-score)	−0.295 ± 1.492^b,e	−2.536 ± 1.497^d	−0.515 ± 1.203^b,c	−2.529 ± 1.240^d	−0.839 ± 1.501^d	−2.930 ± 0.968

Pre-F: premenopausal women; Post-F: postmenopausal women; NB: New Brunswick; CS: Changsha; BMI: body mass index; AKP: alkaline phosphatase; Ca: calcium; 25 (OH) D: 25-hydroxyvitamin D. Significant level . ^aSignificant vs. Pre-F in NB. ^bSignificant vs. Post-F in NB. ^cSignificant vs. Pre-F in CS. ^dSignificant vs. Post-F in CS. ^eSignificant vs. male in CS.